A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis

References

• Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336–1346.
   PubMed Web of Science ®Google Scholar
• Najafi S, Mirshafiey A. The effect of activated microglia in progression of multiple sclerosis. Int Trends Immun. 2015;3:96–104.
   Google Scholar
• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
   PubMed Web of Science ®Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–1024.
   PubMed Web of Science ®Google Scholar
• Aktas O, Ullrich O, Infante-Duarte C, et al. Neuronal damage in brain inflammation. Arch Neurol. 2007;64(2):185–189.
   PubMedGoogle Scholar
• Kuhlmann T, Miron V, Cui Q, et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008;131(Pt 7):1749–1758.
   PubMed Web of Science ®Google Scholar
• Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59(3):478–489.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175–184.
   PubMedGoogle Scholar
• Ntranos A, Lublin F. Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space. Curr Neurol Neurosci Rep. 2016;16(10):90.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Opt Neurol. 2018;20(5):12.
   PubMed Web of Science ®Google Scholar
• Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.
   PubMed Web of Science ®Google Scholar
• Claes N, Fraussen J, Stinissen P, et al. B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions. Front Immunol. 2015;6:642.
   PubMed Web of Science ®Google Scholar
• Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7):78.
   PubMed Web of Science ®Google Scholar
• Rice CM, Cottrell D, Wilkins A, et al. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry. 2013;84(10):1100–1106.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Weber MS, Tumani H. Primary progressive multiple sclerosis: putting together the puzzle. Front Neurol. 2017;8:234.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Taeb M, Mortazavi-Jahromi SS, et al. Introduction of beta-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacol Rep. 2017;69(5):1067–1072.
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol. 2015;37(6):535–540.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol. 2005;27(2):255–265.
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Jamshidi AR, Mahmoudi M, et al. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I/II clinical trial. Int Immunopharmacol. 2018;54:112–117.
   PubMed Web of Science ®Google Scholar
• Ahmadi H, Jamshidi AR, Gharibdoost F, et al. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. 2018;26(3):737–745.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Cuzzocrea S, Rehm B, et al. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol. 2005;61(5):435–441.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Rehm B, Abhari RS, et al. Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol. 2007;24(1):60–66.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Cuzzocrea S, Rehm BH, et al. M2000: a revolution in pharmacology. Med Sci Monit. 2005;11(8):PI53–PI63.
   PubMed Web of Science ®Google Scholar
• Kashefi S, Omranipour R, Mahmoodzadeh H, et al. A randomized, controlled, phase II clinical trial of β-D-mannuronic acid (M2000) in pre-surgical breast cancer patients at early stage (T1-T2). Clin Exp Pharmacol Physiol. 2019;46(6):527–532.
   PubMed Web of Science ®Google Scholar
• Rezaieyazdi Z, Farooqi A, Soleymani-Salehabadi H, et al. International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. 2019;27(5):911–921.
   PubMed Web of Science ®Google Scholar
• Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144–1151.
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MI, Keir G, et al. The new global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler. 2006;12(3):325–328.
   PubMed Web of Science ®Google Scholar
• Manouchehrinia A, Westerlind H, Kingwell E, et al. Age Related Multiple Sclerosis Severity Score: disability ranked by age. Mult Scler. 2017;23(14):1938–1946.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–2015.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Rehm B, Sotoude M, et al. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol. 2007;29(1):49–61.
   PubMed Web of Science ®Google Scholar